Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Janux Therapeutics (JANX) EBITDA (2020 - 2025)

Janux Therapeutics (JANX) has disclosed EBITDA for 6 consecutive years, with -$32.2 million as the latest value for Q4 2025.

  • Quarterly EBITDA fell 24.37% to -$32.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$111.5 million through Dec 2025, down 65.15% year-over-year, with the annual reading at -$111.5 million for FY2025, 65.15% down from the prior year.
  • EBITDA for Q4 2025 was -$32.2 million at Janux Therapeutics, down from -$23.5 million in the prior quarter.
  • The five-year high for EBITDA was -$2.3 million in Q1 2021, with the low at -$33.9 million in Q2 2025.
  • Average EBITDA over 5 years is -$16.6 million, with a median of -$16.3 million recorded in 2023.
  • The sharpest move saw EBITDA tumbled 756.61% in 2021, then soared 60.45% in 2024.
  • Over 5 years, EBITDA stood at -$13.7 million in 2021, then decreased by 11.77% to -$15.3 million in 2022, then skyrocketed by 35.27% to -$9.9 million in 2023, then crashed by 160.98% to -$25.9 million in 2024, then dropped by 24.37% to -$32.2 million in 2025.
  • According to Business Quant data, EBITDA over the past three periods came in at -$32.2 million, -$23.5 million, and -$33.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.